Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease

INTRODUCTION: We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS: This was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelmont, David, Thomas, Ronald G., Britt, Jonathan, Dyck-Jones, Jacqueline A., Doralt, Jennifer, Fritsch, Sandor, Brewer, James B., Rissman, Robert A., Aisen, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644268/
https://www.ncbi.nlm.nih.gov/pubmed/29067300
http://dx.doi.org/10.1016/j.trci.2016.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644268/
https://www.ncbi.nlm.nih.gov/pubmed/29067300
http://dx.doi.org/10.1016/j.trci.2016.06.003

Ejemplares similares